Evidence map›Paper›PMID 41259498›Full record

ArticleEinstein (Sao Paulo, Brazil)2025

Nitazoxanide and nonsteroidal anti-inflammatory drugs (NSAIDs): unveiling the connection in immediate hypersensitivity cross-reactions.

André Luiz Oliveira Feodrippe, Marcelo Vivolo Aun, Elaine Gagete, Jorge Kalil, Pedro Giavina-Bianchi

Abstract readCase Reports
In one paragraph

Article in Einstein (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

André Luiz Oliveira FeodrippeClinical Immunology and Allergy Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0009-0007-6440-1267
Marcelo Vivolo AunClinical Immunology and Allergy Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-9882-5200
Elaine GageteClinical Immunology and Allergy Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-7281-8432
Jorge KalilClinical Immunology and Allergy Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-8415-4274
Pedro Giavina-BianchiClinical Immunology and Allergy Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-1034-7580

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal worm infections, referred to as helminthiases, represent a significant global health challenge, particularly in low- and middle-income countries. These infections affect millions of people and contribute to malnutrition, anemia, and impaired cognitive development, particularly in children. Nitazoxanide, first described in 1975, was initially developed as a veterinary anthelmintic. It has shown efficacy against various pathogens including Giardia lamblia, Entamoeba histolytica, and Cryptosporidium parvum. Recently, its use has expanded due to its observed in vitro activity against viruses, including coronaviruses. Nitazoxanide, a derivative of salicylamide, combines a nitrothiazole moiety with a salicylic acid moiety. Anaphylaxis, a severe immediate hypersensitivity reaction, may be induced by medications, with nonsteroidal anti-inflammatory drugs being among the most common causes. However, neither immediate hypersensitivity reactio, including anaphylaxis, to nitazoxanide nor cross-reactivity with nonsteroidal anti-inflammatory drugs has been previously reported. This study reports four cases of immediate hypersensitivity reactio to nitazoxanide in patients with non-selective immediate hypersensitivity reactio to nonsteroidal anti-inflammatory drugs. These findings highlight the need for vigilance in monitoring medication reactions and suggest the inclusion of nitazoxanide in the list of medications to be avoided in these patients.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalAntiparasitic AgentsDrug HypersensitivityHypersensitivity, ImmediateThiazolesAdultCross ReactionsFemaleHumansMaleMiddle AgedNitro CompoundsAnti-Inflammatory Agents, Non-SteroidalAntiparasitic AgentsnitazoxanideNitro CompoundsThiazoles

Identifiers

PMID41259498
PMCPMC12671640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.